Zymeworks Common Stock Stock Buy Hold or Sell Recommendation
| ZYME Stock | USD 13.40 0.06 0.45% |
Given the investment horizon of 90 days and your way above-average risk tolerance, our recommendation regarding Zymeworks Common Stock is 'Strong Sell'. Macroaxis provides Zymeworks Common buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ZYME positions.
Check out Zymeworks Common Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Zymeworks and provide practical buy, sell, or hold advice based on investors' constraints. Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.
Zymeworks |
Execute Zymeworks Common Buy or Sell Advice
The Zymeworks recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Zymeworks Common Stock. Macroaxis does not own or have any residual interests in Zymeworks Common Stock or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Zymeworks Common's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Zymeworks Common Trading Alerts and Improvement Suggestions
| Zymeworks Common generated a negative expected return over the last 90 days | |
| Zymeworks Common has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 76.01 M. Net Loss for the year was (118.67 M) with loss before overhead, payroll, taxes, and interest of (62.46 M). | |
| Zymeworks Common Stock currently holds about 241.83 M in cash with (118.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.18. | |
| Zymeworks Common has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from zacks.com: Acquisition by Paul Moore of 20000 shares of Zymeworks Common subject to Rule 16b-3 |
Zymeworks Common current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Zymeworks analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Zymeworks analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Zymeworks Common Returns Distribution Density
The distribution of Zymeworks Common's historical returns is an attempt to chart the uncertainty of Zymeworks Common's future price movements. The chart of the probability distribution of Zymeworks Common daily returns describes the distribution of returns around its average expected value. We use Zymeworks Common Stock price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Zymeworks Common returns is essential to provide solid investment advice for Zymeworks Common.
| Mean Return | -0.08 | Value At Risk | -5.98 | Potential Upside | 5.60 | Standard Deviation | 3.36 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Zymeworks Common historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Zymeworks Stock Institutional Investors
| Shares | Farallon Capital Management, L.l.c. | 2024-12-31 | 1.3 M | Nextech Invest Ag | 2024-12-31 | 1.1 M | Tang Capital Management Llc | 2024-12-31 | 1.1 M | State Street Corp | 2024-12-31 | 1.1 M | Samsara Biocapital, Llc | 2024-12-31 | 1000 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 972.7 K | Prosight Management, Lp | 2024-12-31 | 820 K | Bridgeway Capital Management, Llc | 2024-12-31 | 759.7 K | Geode Capital Management, Llc | 2024-12-31 | 689.9 K | Ecor1 Capital, Llc | 2024-12-31 | 15 M | Redmile Group, Llc | 2024-12-31 | 4.8 M |
Zymeworks Common Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Zymeworks Common or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Zymeworks Common's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Zymeworks stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.1 | |
β | Beta against Dow Jones | -0.65 | |
σ | Overall volatility | 3.35 | |
Ir | Information ratio | -0.02 |
Zymeworks Common Volatility Alert
Zymeworks Common Stock exhibits very low volatility with skewness of 0.21 and kurtosis of 0.6. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Zymeworks Common's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Zymeworks Common's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Zymeworks Common Fundamentals Vs Peers
Comparing Zymeworks Common's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Zymeworks Common's direct or indirect competition across all of the common fundamentals between Zymeworks Common and the related equities. This way, we can detect undervalued stocks with similar characteristics as Zymeworks Common or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Zymeworks Common's fundamental indicators could also be used in its relative valuation, which is a method of valuing Zymeworks Common by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Zymeworks Common to competition |
| Fundamentals | Zymeworks Common | Peer Average |
| Return On Equity | -0.29 | -0.31 |
| Return On Asset | -0.15 | -0.14 |
| Profit Margin | (1.83) % | (1.27) % |
| Operating Margin | (2.14) % | (5.51) % |
| Current Valuation | 646.01 M | 16.62 B |
| Shares Outstanding | 68.88 M | 571.82 M |
| Shares Owned By Insiders | 0.17 % | 10.09 % |
| Shares Owned By Institutions | 99.83 % | 39.21 % |
| Number Of Shares Shorted | 3.84 M | 4.71 M |
| Price To Earning | (2.36) X | 28.72 X |
| Price To Book | 2.52 X | 9.51 X |
| Price To Sales | 14.84 X | 11.42 X |
| Revenue | 76.01 M | 9.43 B |
| Gross Profit | (62.46 M) | 27.38 B |
| EBITDA | (120.7 M) | 3.9 B |
| Net Income | (118.67 M) | 570.98 M |
| Cash And Equivalents | 241.83 M | 2.7 B |
| Cash Per Share | 4.18 X | 5.01 X |
| Total Debt | 26.72 M | 5.32 B |
| Debt To Equity | 0.14 % | 48.70 % |
| Current Ratio | 3.29 X | 2.16 X |
| Book Value Per Share | 5.27 X | 1.93 K |
| Cash Flow From Operations | (118.3 M) | 971.22 M |
| Short Ratio | 11.13 X | 4.00 X |
| Earnings Per Share | (1.49) X | 3.12 X |
| Target Price | 20.44 | |
| Number Of Employees | 294 | 18.84 K |
| Beta | 1.09 | -0.15 |
| Market Capitalization | 922.96 M | 19.03 B |
| Total Asset | 580.88 M | 29.47 B |
| Retained Earnings | (677.44 M) | 9.33 B |
| Working Capital | 357.16 M | 1.48 B |
| Net Asset | 580.88 M |
Note: Insider Trading [view details]
Zymeworks Common Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Zymeworks . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Zymeworks Common Buy or Sell Advice
When is the right time to buy or sell Zymeworks Common Stock? Buying financial instruments such as Zymeworks Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Zymeworks Common in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Funds Thematic Idea Now
Consumer Funds
Funds or Etfs that invest in consumer products such as packaged goods, clothing, food, beverages and retail services. The Consumer Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Zymeworks Common Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share | Quarterly Revenue Growth (0.03) | Return On Assets | Return On Equity |
The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.